We're pleased to extend our collaboration which combines our...

We're pleased to extend our collaboration which combines our strengths in analyzing and understanding genetic variation associated with multiple common diseases with Merck's extensive knowledge of the biology underlying neurodegenerative diseases and its global leadership in the development of innovative therapeutics. This target validation program is one example of the value we're able to provide our therapeutic partners worldwide; other examples include identifying individuals who may benefit most from early therapeutic treatment and predict those individuals who will best respond to new therapies.